NASDAQ:FBIO Fortress Biotech - FBIO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Fortress Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.75 +0.01 (+1.34%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.73▼$0.7950-Day Range$0.66▼$1.1052-Week Range$0.48▼$1.53Volume212,030 shsAverage Volume837,657 shsMarket Capitalization$85.58 millionP/E RatioN/ADividend YieldN/APrice Target$6.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Fortress Biotech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside695.3% Upside$6.00 Price TargetShort InterestHealthy0.51% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.93Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.85) to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.41 out of 5 starsMedical Sector220th out of 1,005 stocksPharmaceutical Preparations Industry92nd out of 486 stocks 3.5 Analyst's Opinion Consensus RatingFortress Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.00, Fortress Biotech has a forecasted upside of 695.3% from its current price of $0.75.Amount of Analyst CoverageFortress Biotech has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.51% of the float of Fortress Biotech has been sold short.Short Interest Ratio / Days to CoverFortress Biotech has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Fortress Biotech has recently decreased by 22.09%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldFortress Biotech does not currently pay a dividend.Dividend GrowthFortress Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for FBIO. Previous Next 3.3 News and Social Media Coverage News SentimentFortress Biotech has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Fortress Biotech this week, compared to 1 article on an average week.Search InterestOnly 8 people have searched for FBIO on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat Follows9 people have added Fortress Biotech to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Fortress Biotech insiders have not sold or bought any company stock.Percentage Held by Insiders26.30% of the stock of Fortress Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 27.91% of the stock of Fortress Biotech is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Fortress Biotech are expected to decrease in the coming year, from ($0.85) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fortress Biotech is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fortress Biotech is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFortress Biotech has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Fortress Biotech (NASDAQ:FBIO) StockFortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.Read More Receive FBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address FBIO Stock News HeadlinesMarch 22, 2023 | finance.yahoo.comJourney Medical Corporation to Announce Year End 2022 Financial Results on March 29, 2023March 7, 2023 | finance.yahoo.comFortress Biotech to Participate in Two March 2023 Investor ConferencesMarch 26, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …March 7, 2023 | finance.yahoo.comJourney Medical Corporation to Participate in the 35th Annual ROTH ConferenceMarch 2, 2023 | finance.yahoo.comCheckpoint Therapeutics Announces FDA Filing Acceptance of Biologics License Application for Cosibelimab in Metastatic or Locally Advanced Cutaneous Squamous Cell CarcinomaMarch 2, 2023 | finance.yahoo.comAvenue Therapeutics Enters into a Transformational License Agreement with AnnJi Pharmaceutical to Develop and Commercialize AJ201, a First-in-Class Clinical Asset for the Treatment of Spinal and Bulbar Muscular AtrophyFebruary 19, 2023 | finance.yahoo.comThe Executive Chairman of Fortress Biotech, Inc. (NASDAQ:FBIO), Lindsay Rosenwald, Just Bought 18% More SharesFebruary 16, 2023 | finance.yahoo.comHelocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRMarch 26, 2023 | Weiss Ratings (Ad)Urgent WarningThis was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …February 15, 2023 | finance.yahoo.comStudy Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with TriplexFebruary 10, 2023 | finance.yahoo.comFortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq RulesJanuary 28, 2023 | finance.yahoo.comInsiders own 28% of Fortress Biotech, Inc. (NASDAQ:FBIO) shares but individual investors control 41% of the companyJanuary 20, 2023 | finance.yahoo.comJourney Medical Corporation Appoints Joseph Benesch as Interim Chief Financial OfficerJanuary 17, 2023 | finance.yahoo.comMustang Bio to Participate in the B. Riley Securities’ 3rd Annual Oncology ConferenceJanuary 17, 2023 | finance.yahoo.comCheckpoint Therapeutics to Participate in the B. Riley Securities’ 3rd Annual Oncology ConferenceDecember 20, 2022 | finance.yahoo.comJourney Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29December 15, 2022 | finance.yahoo.comCheckpoint Therapeutics Announces $7.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesDecember 14, 2022 | finance.yahoo.comUrica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North AfricaDecember 6, 2022 | finance.yahoo.comFortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic ConferenceNovember 15, 2022 | finance.yahoo.comMustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate HighlightsNovember 15, 2022 | finance.yahoo.comFortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue EstimatesNovember 8, 2022 | finance.yahoo.comAvenue Therapeutics Completes the Acquisition of Baergic Bio and its Selective GABA-A α2/3 Receptor Positive Allosteric Modulator for the Treatment of Central Nervous System DisordersOctober 27, 2022 | finance.yahoo.comMustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's MacroglobulinemiaOctober 26, 2022 | finance.yahoo.comInsider Buying: The Fortress Biotech, Inc. (NASDAQ:FBIO) Executive Chairman Just Bought US$70k Worth Of SharesOctober 7, 2022 | seekingalpha.comFortress Biotech, Inc. 9.375% CUM RED PER PREF SER A USD25.00 declares $0.1953 dividendOctober 6, 2022 | markets.businessinsider.comEQS-News: Fortress Bios Portfolio Of Marketed Drugs Could Soon See Three AdditionsOctober 6, 2022 | finance.yahoo.comFortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three AdditionsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive FBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fortress Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address FBIO Company Calendar Last Earnings11/15/2021Today3/25/2023Next Earnings (Estimated)3/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:FBIO CUSIP21976U10 CIK1429260 Webwww.fortressbiotech.com Phone(781) 652-4500Fax781-652-4545Employees173Year FoundedN/APrice Target and Rating Average Stock Price Forecast$6.00 High Stock Price Forecast$6.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+695.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-64,700,000.00 Net Margins-117.49% Pretax Margin-289.25% Return on Equity-54.56% Return on Assets-24.45% Debt Debt-to-Equity Ratio0.91 Current Ratio2.43 Quick Ratio2.28 Sales & Book Value Annual Sales$68.79 million Price / Sales1.24 Cash FlowN/A Price / Cash FlowN/A Book Value$2.27 per share Price / Book0.33Miscellaneous Outstanding Shares113,440,000Free Float83,607,000Market Cap$85.58 million OptionableOptionable Beta1.97 Key ExecutivesLindsay Allan RosenwaldChairman, President & Chief Executive OfficerDavid JinCFO & Head-Corporate DevelopmentGeorge C. AvgerinosSenior Vice President-Biologics OperationsMichael Sean WeissDirector & Executive Vice Chairman-StrategyBrian AchenbachVice President-Finance & ControllerKey CompetitorsVerastemNASDAQ:VSTMBolt BiotherapeuticsNASDAQ:BOLTSpectrum PharmaceuticalsNASDAQ:SPPIMerrimack PharmaceuticalsNASDAQ:MACKXOMANASDAQ:XOMAView All CompetitorsInsiders & InstitutionsNantahala Capital Management LLCSold 294,996 shares on 2/15/2023Ownership: 7.396%Jefferies Financial Group Inc.Bought 4,300,000 shares on 2/15/2023Ownership: 3.991%CI Private Wealth LLCBought 792,267 shares on 2/15/2023Ownership: 0.735%Millennium Management LLCSold 58,862 shares on 2/15/2023Ownership: 0.240%Morgan StanleyBought 15,392 shares on 2/15/2023Ownership: 0.100%View All Insider TransactionsView All Institutional Transactions FBIO Stock - Frequently Asked Questions Should I buy or sell Fortress Biotech stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fortress Biotech in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FBIO shares. View FBIO analyst ratings or view top-rated stocks. What is Fortress Biotech's stock price forecast for 2023? 4 Wall Street research analysts have issued twelve-month price objectives for Fortress Biotech's stock. Their FBIO share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 695.3% from the stock's current price. View analysts price targets for FBIO or view top-rated stocks among Wall Street analysts. How have FBIO shares performed in 2023? Fortress Biotech's stock was trading at $0.6550 at the beginning of the year. Since then, FBIO stock has increased by 15.2% and is now trading at $0.7544. View the best growth stocks for 2023 here. When is Fortress Biotech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023. View our FBIO earnings forecast. How were Fortress Biotech's earnings last quarter? Fortress Biotech, Inc. (NASDAQ:FBIO) announced its quarterly earnings data on Monday, November, 15th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by $0.06. The biopharmaceutical company had revenue of $21.09 million for the quarter, compared to analyst estimates of $18.41 million. Fortress Biotech had a negative net margin of 117.49% and a negative trailing twelve-month return on equity of 54.56%. What other stocks do shareholders of Fortress Biotech own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fortress Biotech investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Novavax (NVAX), Advanced Micro Devices (AMD), OPKO Health (OPK), TG Therapeutics (TGTX), Vaxart (VXRT), NVIDIA (NVDA), Pfizer (PFE) and Dynavax Technologies (DVAX). What is Fortress Biotech's stock symbol? Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO." Who are Fortress Biotech's major shareholders? Fortress Biotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include Nantahala Capital Management LLC (7.40%), Jefferies Financial Group Inc. (3.99%), Opaleye Management Inc. (1.90%), Perkins Capital Management Inc. (0.76%), CI Private Wealth LLC (0.74%) and Millennium Management LLC (0.24%). Insiders that own company stock include Eric K Rowinsky, Lindsay A Md Rosenwald, Malcolm Hoenlein and Robyn Hunter. View institutional ownership trends. How do I buy shares of Fortress Biotech? Shares of FBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Fortress Biotech's stock price today? One share of FBIO stock can currently be purchased for approximately $0.75. How much money does Fortress Biotech make? Fortress Biotech (NASDAQ:FBIO) has a market capitalization of $85.58 million and generates $68.79 million in revenue each year. The biopharmaceutical company earns $-64,700,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. How many employees does Fortress Biotech have? The company employs 173 workers across the globe. How can I contact Fortress Biotech? Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The official website for the company is www.fortressbiotech.com. The biopharmaceutical company can be reached via phone at (781) 652-4500, via email at ir@fortressbiotech.com, or via fax at 781-652-4545. This page (NASDAQ:FBIO) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.